Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Your search for KCNQ1 returned no results
Showing 1 to 4 of 4 results for kccq

  1. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA902

  2. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA773

  3. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA679

  4. Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)

    Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.

    HealthTech guidance
    Published
    5 February 2026
    View recommendations

    Sections for HTG769